Astrana Health, Inc. cash flow statement ASTH

In the fiscal 2026 year to date through Jun 30, 2026, Astrana Health, Inc. generated $100.8 million of cash from operations, up 10.9% from the same quarter a year earlier. It spent $7.9 million on capital expenditures. That left free cash flow of $92.9 million. The company returned $199,000 in dividends and $2.8 million in share buybacks to shareholders.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jun 30, 2026
Q2 FY2026 YTD
Jun 30, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Q2 FY2024
Jun 30, 2024
Operating
Depreciation and amortization
63
+116.3%
31
+349.5%
16
+101.8%
16
+114.7%
7
-7.2%
7
+34.4%
8
+65.8%
7
+68.7%
7
+75.1%
Stock-based compensation
41
-0.4%
22
+85.2%
11
-25.3%
8
+24.9%
12
+58.4%
8
+35.9%
15
+75.6%
6
+8.0%
7
+75.4%
Operating cash flow
108
-17.4%
101
+10.9%
-3
+73.6%
10
-70.7%
91
+292.0%
17
+178.2%
-11
-156.7%
34
+120.6%
23
-10.1%
Investing
Capital expenditures
13
+44.8%
8
+454.8%
3
+21.1%
3
+11.2%
1
-49.9%
3
+732.0%
3
-64.1%
2
-44.1%
3
-75.0%
Investing cash flow
-545
-1112.9%
-9
-742.3%
-1
+96.8%
-534
-6492.7%
-1
+98.7%
-2
+96.6%
-33
-191.6%
-8
+76.8%
-80
-1441.2%
Financing
Dividends paid
2
-77.9%
0
-74.4%
2
-19.0%
0
-56.0%
1
-56.8%
5
+5642.1%
2
0
-84.7%
2
+149.4%
Stock buybacks
18
3
-64.1%
15
0
8
—
—
—
—
Financing cash flow
502
+804.6%
-120
-1289.6%
-26
-72.5%
648
+20428.9%
-9
-118.3%
-44
-141.5%
-15
-227.3%
-3
-525.5%
47
+5006.7%
Change in cash
Net change in cash
65
+354.3%
-28
-134.9%
-30
+49.1%
124
+446.5%
81
+955.9%
-30
-172.5%
-60
-399.7%
23
+213.5%
-9
-148.3%
Free cash flow
94
-22.2%
93
+3.8%
-6
+55.9%
7
-76.6%
89
+339.7%
14
+141.7%
-13
-210.1%
32
+180.4%
20
+40.7%
Per share
Free cash flow per share
1.91
-23.5%
1.87
+3.2%
-0.12
+57.2%
0.15
-77.2%
1.81
+326.4%
0.28
+136.0%
-0.28
-208.1%
0.66
+172.8%
0.42
+37.2%
Shareholder returns
Returned to shareholders
20
3
17
0
9
5
2
0
2
Share of free cash flow
20.82%
3.23%
—
1.30%
9.59%
40.24%
—
0.69%
8.85%
Ratios
Free cash flow margin
2.46%
9.56%
-0.63%
0.77%
13.67%
2.19%
-2.03%
6.62%
4.19%
Capital expenditures to revenue
0.35%
0.81%
0.32%
0.27%
0.22%
0.49%
0.38%
0.48%
0.58%
Stock-based compensation to revenue
1.06%
2.23%
1.20%
0.81%
1.79%
1.26%
2.29%
1.29%
1.52%
Cash conversion
2.66x
5.11x
-0.48x
26.69x
9.65x
2.48x
—
2.11x
1.21x
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Services-Management Consulting Services (SIC 8742)
Listed as
ASTH (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Alhambra, CA
SEC filer status
Large accelerated filer
SEC CIK
1083446
Former names
Apollo Medical Holdings, Inc. (until Feb 13, 2024); SICLONE INDUSTRIES INC (until Jul 15, 2008)

Other Services-Management Consulting Services companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.